Available from: Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes state-of-the-art
Glatter: Another important option that deserves earlier considerationnot later referralis metabolic and bariatric surgery
Mostly in lab studies looking at cellular health, tissue regeneration, and oxidative stress reduction
When G6PD activity is deficient, NADPH levels fall, increasing the likelihood of RBC eNOS uncoupling, where the enzyme generates ROS instead of NO (Snezhkina et al., 2019)
A distinctive effect from the phase 3 data is dysesthesia, a skin-sensation symptom described as tingling or sensitivity, more common at higher doses